BCO SANTANDER N.EO0,5/ ES0113900J37 /
31.05.2024 8:10:28 | Изменение +0.111 | Объем сделки | Бид21:59:32 | Предложение21:59:32 | Рыночная капитализация | Дивидендная доходность | Коэффициент Цена/Доход |
---|---|---|---|---|---|---|---|
4.770EUR | +2.37% | 0 Оборот: 0.000 |
-Величина цены спроса: - | -Величина цены предложения: - | 78.24 млрдEUR | 3.64% | 7.39 |
GlobeNewswire
21:00
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
GlobeNewswire
19:39
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 ...
GlobeNewswire
19:02
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
16:00
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
16:00
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
16:00
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
15:14
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
15:00
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
15:00
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
14:15
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
14:15
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница